/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, applauds the recently announced Centers for.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, applauds the recently announced Centers for.
Share this article
Share this article
SHANGHAI, Jan. 6, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Breast Cancer is Singapore s number one leading cause of cancer death in women and TNBC accounts for 15-20% of all breast cancer in Singapore. This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest s licensed territory, which also includes Greater China, South Korea, and certain additional South